KCNJ8
ATP-sensitive inward rectifier potassium channel 8
As of the edition of 20 October 2026, KCNJ8 (ATP-sensitive inward rectifier potassium channel 8, UniProt Q15842) has 1 drug tested at it and 3 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q15842
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Disease areas
- Nutrition and metabolism; Hormones; Inherited and neonatal; Heart and blood vessels; Immune system; Nervous system; Digestive system; Pregnancy and women's health
- Registered trials of its drugs
- 27
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Diazoxide | Marketed | Phase 4 | none listed |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Engaged | 3 |
| Total on the list | 3 |